ASCO 2023 | Advancing fecal microbiota transplantation: immune-mediated colitis treatment

Yinghong Wang, MD, PhD, from The University of Texas MD Anderson Cancer Center, provides insights into fecal microbiota transplantation (FMT) and its use as a first-line treatment for immune-mediated colitis. FMT has been established in clinical practice for over 15 years, primarily for recurrent clostridium difficile (C. diff) infection, showing superior success rates compared to antibiotics. Recently, FMT’s application has extended to investigational treatments for various medical disorders beyond C. diff infection. This discussion took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.